News & Events

Dr. Ann Hanham Joins HTG Molecular Diagnostics’ Board of Directors

TUCSON, Ariz., Aug. 29, 2016 (GLOBE NEWSWIRE) -- HTG Molecular Diagnostics, Inc. (Nasdaq:HTGM), a provider of instruments and reagents for molecular profiling applications, today announced that Ann F. Hanham, Ph.D. has been appointed to its Board of Directors (“Board”).

Ann Hanham is a senior health care executive with experience working with both private and public companies.  Dr. Hanham possesses a diverse background in global clinical and regulatory development, finance, and corporate strategy. She has extensive experience in developing pharmaceutical, diagnostic and medical device products with a proven track record of clinical and regulatory approvals, building businesses, and creating shareholder value.

Full press release

Posted on:

Return To List

Page last updated December 19, 2017